DoD Neurofibromatosis, Clinical Trial Award | W81XWH 19 NFRP CTA

Opportunity Information: Apply for W81XWH 19 NFRP CTA

The Department of Defense Neurofibromatosis Research Program (NFRP) Clinical Trial Award is a discretionary research funding opportunity meant to push forward clinical trials that could meaningfully improve how neurofibromatosis (NF) is treated or managed. The core aim is high-impact, patient-relevant clinical research, with an emphasis on studies that can change clinical practice, open up new therapeutic options, or generate strong evidence to guide care. The award is structured to support trials that test interventions and strategies with clear promise, rather than early exploratory laboratory work that is not ready for human evaluation.

This opportunity specifically funds clinical trials across a wide spectrum of readiness and scale. On the early end, it can support small proof-of-concept efforts such as pilot studies, first-in-human investigations, or Phase 0 trials, where the goal is to establish feasibility, assess early safety signals, refine endpoints, or collect preliminary data that will shape later-stage trial design. On the more advanced end, it can also support larger trials intended to determine efficacy in relevant NF patient populations, meaning studies that are designed to answer whether an intervention actually works for the intended clinical purpose and for the people most affected by the condition.

The types of trial interventions contemplated are broad and include promising new products, pharmacologic agents such as drugs or biologics, medical devices, clinical guidance approaches (for example, structured care pathways or management strategies that can be tested in a controlled way), and emerging approaches or technologies. In practical terms, the program is signaling that it is open to both therapeutic and management-oriented trials, as long as the proposed work is rigorous, clinically grounded, and positioned to deliver actionable results for NF patients and clinicians.

Administratively, the sponsoring agency is the Department of Defense, Department of the Army, through the U.S. Army Medical Research Acquisition Activity (USAMRAA). The listed funding instruments include both cooperative agreements and grants, which typically indicates that applicants may need to be prepared for either standard grant management or a more collaborative model where the funder has substantial involvement in project oversight, milestones, and coordination. The activity category is Science and Technology and other Research and Development, and the associated CFDA number is 12.420. Eligibility is described as unrestricted, meaning any type of applicant organization may apply, subject to any additional eligibility language in the full announcement. The opportunity number is W81XWH 19 NFRP CTA, it was created March 11, 2019, and the original closing date was June 6, 2019. The listing notes an expected number of awards of 1, and the award ceiling is shown as 0 in the source record, which often means the ceiling was not specified in that particular summary field and would need to be confirmed in the full funding announcement and related budget guidance.

Overall, the NFRP Clinical Trial Award is aimed at supporting well-justified, well-designed NF clinical trials that are positioned to produce results that can directly affect patient care, whether by demonstrating feasibility for a new approach, generating evidence needed to advance to later-stage testing, or definitively evaluating efficacy in the NF population.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Neurofibromatosis, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 11, 2019.
• Applicants must submit their applications by Jun 06, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 NFRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: